The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:709 August 14, 2003 Number 7
NextNext

A Novel Coronavirus and SARS

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Ksiazek, T. G.
-PubMed Citation
To the Editor: Ksiazek et al. (May 15 issue)1 report that there is antibody cross-reactivity between serum from a patient with severe acute respiratory distress syndrome (SARS) and antibodies that are reactive with group I coronaviruses. This finding raises the possibility of using existing vaccines against these heterologous coronaviruses for protection against SARS. Unfortunately, the study did not show any virus-neutralization activity. Nevertheless, the close similarity between the SARS open reading frame 1b and other human and animal coronaviruses lends support to the idea of using heterologous coronaviral strains, which are harmless to humans, as vaccines. There are several historical . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.